You just read:

OncoSec Granted FDA Fast Track Designation for ImmunoPulse® IL-12 for the Treatment of Metastatic Melanoma Following Progression on Pembrolizumab or Nivolumab

News provided by

OncoSec Medical Incorporated

Feb 27, 2017, 06:01 ET